drugset / Trial / NCT04068597
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Timeline
- Start
- 2019-08-09
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inobrodib | Small molecule | — | Oral |
| Background | Azacitidine | Other / unclassified | — | — |
| Background | Bortezomib | Small molecule | — | — |
| Background | Daratumumab | Monoclonal antibody | — | — |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Elranatamab | Monoclonal antibody | — | — |
| Background | Ixazomib | Unknown | — | Oral |
| Background | Lenalidomide | Other / unclassified | — | Oral |
| Background | Pomalidomide | Other / unclassified | — | Oral |
| Background | Teclistamab | Monoclonal antibody | — | — |
| Background | Venetoclax | Small molecule | — | Oral |